WO2008041045A1 - Récipient à chambres multiples pour la production et la distribution de mousse de dioxyde de carbone, procédé de production et utilisation de ladite mousse - Google Patents
Récipient à chambres multiples pour la production et la distribution de mousse de dioxyde de carbone, procédé de production et utilisation de ladite mousse Download PDFInfo
- Publication number
- WO2008041045A1 WO2008041045A1 PCT/HU2006/000113 HU2006000113W WO2008041045A1 WO 2008041045 A1 WO2008041045 A1 WO 2008041045A1 HU 2006000113 W HU2006000113 W HU 2006000113W WO 2008041045 A1 WO2008041045 A1 WO 2008041045A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- container
- carbon dioxide
- compartment
- foam
- carbonate
- Prior art date
Links
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 title claims abstract description 206
- 229910002092 carbon dioxide Inorganic materials 0.000 title claims abstract description 104
- 239000001569 carbon dioxide Substances 0.000 title claims abstract description 102
- 239000006260 foam Substances 0.000 title claims abstract description 46
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 15
- 239000007789 gas Substances 0.000 claims abstract description 46
- 239000000463 material Substances 0.000 claims abstract description 33
- 239000004615 ingredient Substances 0.000 claims abstract description 29
- 239000002537 cosmetic Substances 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 14
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 11
- 239000003599 detergent Substances 0.000 claims abstract description 10
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 206010047141 Vasodilatation Diseases 0.000 claims description 7
- 230000024883 vasodilation Effects 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 239000002453 shampoo Substances 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 5
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960004424 carbon dioxide Drugs 0.000 description 94
- 239000000243 solution Substances 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- 238000011282 treatment Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 8
- 229940124549 vasodilator Drugs 0.000 description 7
- 239000003071 vasodilator agent Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 244000193463 Picea excelsa Species 0.000 description 1
- 235000008124 Picea excelsa Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- XNVWFBHTEBDKCA-UHFFFAOYSA-N butanedioic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O XNVWFBHTEBDKCA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/22—Gas releasing
- A61K2800/222—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
Definitions
- the invention relates to a two-compartment container providing stable carbon dioxide foam, and by the help of this a process for production of carbon dioxide foam from two components on a skin surface. These two components fusing on the skin surface form carbon dioxide where this carbon dioxide takes on the form of stable foam in consequence of the delaying and stabilizing effect of the present surface-active
- the invention further relates to a process for using the foam to cause vasodilatation in the subcutaneous tissues from cosmetic and/or therapeutic aim.
- HU 220349 and HU 1974729 Hungarian patents relate to possibilities of domestic application of the carbon dioxide baths according to which carbon dioxide is introduced to the domestic bath water from a container or a siphon cartridge available in the trade.
- U 3015 Hungarian utility model is connected with the gas chamber ("mofette") treatment which gives a solution for gas chamber treatment with carbon dioxide gas; this consists of a house applied around a part of body into which the carbon dioxide can be introduced from outside, from a gas cylinder.
- mofette effect which is the basis of the solution of the present invention, too
- a lot of literary data can be found on address http://hu.wikipedia.org.wiki/Mofetta.
- a Hungarian patent application filed on N° P9000163 and published on N° 58649 deals with the insufflating treatment and its instrument; its essence is an insufflating treatment by a needle from which itself the sterile carbon dioxide gas originates from reagents of suitable composition and of suitable quality.
- the present invention is classed among the above specified forms into the category of "direct topical intake of the carbon dioxide gas through skin”. It can really be considered as a sub-category of the solution of "staying in a room containing carbon dioxide gas” but this solution deviates in that from the other solution that it deals with carbon dioxide treatment of smaller parts of body or skin surfaces instead of the exposure of the whole body or bigger parts of body to the carbon dioxide gas.
- Patent document US 2003/0139696 makes known an in situ applicable pillow by the help of which it is possible to place serious wounds under carbon dioxide pressure.
- the role of the carbon dioxide is to press tightly the wound to avoid the loss of blood.
- Both the aim (to guarantee pressure) and the technical execution (e.g. providing carbon dioxide from cylinder and using closed bandage) deviate from the solution of the present invention.
- the essence according to the solution of the present invention is, however, that the carbon dioxide gas is formed in the skin surface in such manner that two components, staying in a two-compartment container where one of the compartments contains some kind of preferably sterile acid and the other compartment contains some kind of preferably sterile carbonate or hydrogen carbonate, are pressed out together from the container, they combine together in the skin surface and step into reaction here with each other.
- the toxicological and microbiological quality of the carbon dioxide can be guaranteed with the purity of the starting acid and carbonate and by possible sterilising to the desired extent.
- the surface-active materials (detergents) also placed in one or both container compartment guarantee that the formation of the carbon dioxide should be retarded and the formed foam should be preserved at least as long as the formed carbon dioxide exposes its therapeutic (vasodilator) effect under the skin surface. For this aim 5-10 minutes is sufficient, and this period can be guaranteed with the stable foam.
- the foam containing carbon dioxide is able to give that minimal pressure surplus which facilitates the penetration of the carbon dioxide into the skin.
- the present invention is based on the employment of the carbon dioxide gas directly evolving by the double decomposition reaction.
- the already activating chemical reaction is maintained by the continuously releasing water on the basis of the following reaction: CO 3 " + 2H + -» CO 2 + H 2 O
- reaction partners to be found in the foam-forming mixture is not too essential; it is important only that at the meeting of the reaction partners and the water carbon dioxide of suitable amount should be formed.
- the conditions are the same as in the case of effervescent tablets, powders or granules based on similar reaction, although the point of views of the selection are not exactly the same.
- the main thing is that the formed ions should not be caustic, toxic or bad-tasting (rather should be good to the taste, respectively), in the present situation the main point of view is that the generating ions should not exercise caustic or toxic influence to the skin; the point of views of flavour does not play role here.
- the calcium carbonate can be advantageous not only from point of view of the costs but from the point of views of optionally necessary retardation of the foam-forming, since the generation of the carbon dioxide gas is relatively slow from the calcium carbonate granules. It is inevitably necessary to take into consideration at the selection of the ingredients that the ingredients should be able to get across the opening of a feeding equipment. Of course, it is possible to draw up reversely: such feeding equipment should be employed which fits to the physicochemical properties of the given advantageous mixture.
- a container (bottle, tube, flacon and the like) which is provided with a separation wall and suitable dosing equipment. Its function is to receive acidic and carbonate ingredients, respectively, and foam-forming surface-active (detergent) materials, further ingredients and optionally different pharmacons, respectively, and it have to able to place the different materials onto the skin surface in a suitable proportion by the help of a suitably formed dosing equipment from the two container compartments; Neither the empty container itself nor the dosing equipment itself nor their formation constitutes the subject-matter of the invention; every solution is applicable which is able to perform the above functions.
- the dosing equipment has not to be a complicated construction.
- the dosing equipment e.g. can be a dosing equipment which can be screwed onto the container.
- the outflow of the material is provided by the pressure, mainly hand-power pressure applied onto the container.
- an extrusive roll can provide the getting out from the two container compartments in suitable proportion.
- the formation of the two-compartment container can be solved in various ways.
- One of the solutions can be that the separation wall is formed in advance from the container's material.
- a bag made from some kind of plastic, preferably a polyalkylene, first of all polyethylene, can be placed into a suitable container. This is a suitable solution first of all for that reason since it is not necessary to modify the production technique of a very cheaply available container, only a filling have to be used into it.
- the main point of view is that this equipment should be able to dispatch the materials from both container compartment in the in advance suitably adjusted proportion taking into consideration the physical condition (consistency, grain size and the like) of the individual materials (material compositions). Consequently at the selection of the two-compartment container and its dosing equipment the main point of views are the fitting to the components, the steady convej ⁇ ng of the materials as well as economic point of views.
- Figure 1 is a section of a scheme of a possible execution example.
- Figure 1 makes known schematically a possible solution to a suitable container.
- the device outlined in Figure 1. is an elastic- walled 1 container (bottle, flacon) which is divided into two parts with a 2 separation wall and is supplied with a 5 dosing equipment which represents an elastic-walled compressible material.
- the figure shows the 3 and 4 container compartments of 1 container supplied the 2 separation wall, the 6 lower closing valve, the 7 outer closing valve and the 8 outlet opening.
- the surface-active materials (detergents) providing the foam formation and foam stability promote both the stability of the foam and necessary delaying or maybe accelerating the evolution of the carbon dioxide.
- these materials can be sodium lauryl sulphate, triethanolamine, polysorbates (e.g. Polysorbate 20) and sterols e.g. cholesterol.
- Delaying and accelerating the chemical reaction depends on the hydrophilic-hydrophilic combination of the ingredients. The most retarded reaction takes place in the lipophilic-lipophilic suspension combination of the materials in the two 3, 4 container compartments. The quickest reaction can be realized by the mixture of the hydrophilic-hydrophilic combination containing dissolved carbonates.
- cosmetic basic materials which form the suitable consistence of the preparation (cream, shampoo and other cosmetic preparations) in the condition after disappearance of the formed foam.
- These preparations i.e. should not be removed after leaving of the carbon dioxide but they can remain on the skin surface as cosmetics.
- To these ingredients examples can be - without the intention of limitation - cetyl alcohol stearate, glycerine, methyl cellulose, vaseline, solid and/or liquid paraffin, white wax, castor oil, gelatine, xanthan gum, etc., but the water itself, too.
- the pharmacons intensifying the healing power intensify the healing power of the preparation first of all in that 5-10 minutes until the carbon dioxide gas performs its vasodilator effect but also after removing the carbon dioxide together with the cosmetics actually as a part of the cosmetics.
- the pharmacons being in question can move in a wide domain depending in the given therapeutic field; e.g. preparations recommendable to the treatment of locomotor's diseases can contain volatile oils, e.g. the volatile oils of camomile, eucalyptus and Scotch fir, but they can contain also capsaicin, camphor, menthol and methyl salicylate.
- the acid and the carbonate should not get into the same compartment.
- the solution that which of the further ingredients (detergents providing foam formation and foam stability, cosmetic basic materials, pharmacons intensifying healing power) gets into the acidic compartment and which of the further ingredients gets into the carbonate compartment, is decided only according to technological advantages (compatibility, the ease of getting out). It is imaginable, too, that individual ingredients can be found both in the 3 container compartment and the 4 container compartment, if this solution has a technological advantage.
- a filled two-compartment 1 container flacon, flask, bottle, tube
- container contains in its 3 container compartment an acid of suitable amount and its other 4 container compartment some kind of carbonate or hydrogen carbonate, it contains further in its 3 container compartment or in its 4 container compartment or in both 3, 4 container compartments surface-active materials (detergents), cosmetic basic materials and optionally different pharmacons.
- the filled two-compartment 1 container is provided with such a 5 dosing equipment which guarantees that the ingredients should get from two 3, 4 container compartments to the selected surface, in this situation to skin surface, in an in advance adjusted proportion.
- the said filled 1 container have to satisfy the following point of views:
- the filling into the bottles and the closing of the bottle with the 5 dosing equipment is a well mechanized technology having almost century-old tradition.
- the employment of the filled 1 container as a product is accomplishable easily by simple pushing a button.
- the filled 1 container as a product is strong and firm, well storable and maintainable for a long time without quality deterioration since the ingredients being in the individual 3, 4 container compartments are not able to react with each other within the container compartment.
- the said product however, can be » produced from cheap basic materials and by an established technology.
- the 1 container- filled with the said ingredients and suitable for forming stable foam is not only new but it can become to a product producible cheaply and saleable well in trade.
- the filling of the elastic-walled, two-compartment 1 containers, tubes does not imply technological problem, neither, since there are available established technologies for this aim, too.
- Another subject-matter of the present invention is the production of a preparation including stable foam containing carbon dioxide gas for causing vasodilatation under the skin.
- the evolving carbon dioxide gas should quickly reach to the skin surface from the site of the reaction; • the carbon dioxide gas should be in contact uniformly and continuously with the skin surface; • it is necessary that the carbon dioxide gas should evolve permanently at least during 5-10 minutes;
- the instrument providing carbon dioxide here the preparation itself originating on the skin surface and including stable foam containing carbon dioxide gas.
- the originating carbon dioxide gas has not to "reach" the surface of skin, either, since it originates there. For the same reason the uniform, continuous contact is guaranteed with the skin surface.
- the stability of the foam guarantees that minimal pressure surplus compared to the atmospheric pressure which promotes the penetration of the carbon dioxide into the skin.
- the foam containing carbon dioxide gas is suitable as a- vasodilator preparation from every point of view. Its production is easily realisable by the help of the two-compartment 1 container which is the previous subject- ⁇ matter of the invention.
- the carbon dioxide gas prepared on this way does not contain the (first of all pyrogenic) impurities of the industrial carbon dioxide gas; the purity of the gas can be guaranteed according to the demands by the suitable purity of the reaction partners fmdable in granules or powder; by their sterilization, however, it is possible to guarantee the sterility of the gas if necessary.
- a further subject-matter of the invention is the use of the foam containing carbon- dioxide gas for causing vasodilatation in the tissues to be found under skin.
- the penetration of the carbon dioxide under skin surface causes vasodilatation.
- the penetration of the carbon dioxide is promoted by the stable foam according to the invention during the necessary 5-10 minutes
- the stable foam containing carbon dioxide can be taken up to the selected skin surfaces and only to the selected skin surfaces, by the help of this solution the skin surface to be treated can be well surrounded. This is especially advantageous where the forwarding the carbon dioxide is realizable by other means only with serious difficulties as e.g. on the hairy on non-hairy scalp, but this preparation can be utilized every other treatable skin surface, too.
- the stable foam containing carbon dioxide gas can occur e.g. in massaging ("warming") creams used by sportsmen, in preparations used on surfaces requiring physiotherapy, in cosmetic products (e.g. face-packs) and the like.
- the application consists in that the stable foam containing carbon dioxide and prepared on the way introduced previously is carried up to the selected areas (surfaces) where the carbon dioxide to be found in the foam displays its vasodilator effect under the skin surface during 5-10 minutes.
- the question whether the foam containing carbon dioxide should be carried up in what thickness onto the surface to be treated is very difficult to be decided since it strongly depend on the nature of the ingredients. The essence is that this thickness of layer should guarantee the penetration of the carbon dioxide gas for 5- 10 minutes. After leaving the carbon dioxide gas the preparation can remain on the skin surface and can display its further therapeutic- and cosmetic effect.
- Example 1 Filled two-compartment container as a commercial product for preparing a stable shampoo containing carbon dioxide gas
- the above prescription relates to 1000 g of product; the concrete amount is decided depending on whether the two-compartment 1 container putting on the market has what dimension. The proportions of the ingredients, however, are acceptable at whatever dimension, consequently at this packaging of 300 g, too.
- the two-compartment 1 container is supplied with a suitable 5 dosing equipment.
- the 5 dosing equipment indicates such a solution which can be opened by pressing down an usual springy closing valve.
- An expanded spring moves the piston placed at the end of 1 container which empties uniformly the content of the two 3, 4 container compartments.
- the product obtained in this manner and being able to put into the trade is the subject-matter of the invention.
- Example 2 Filled two-compartment container as a commercial product for preparing massaging ("warming") sport cream containing carbon dioxide
- a two-compartment, elastic-walled 1 container (tube) of 200 millilitre available in the trade is filled. Into the two 3, 4 container compartments the followings are fed:
- the above prescription relates to 1000 g of product, the concrete amount is decided depending on whether what dimension has the two-compartment 1 container putting on the market.
- the proportions of the ingredients are acceptable at whatever dimension, consequently at this tube of 200 ml, too.
- the material can be helped to get out by manual pressure from the tube, from the two 3, 4 container compartments.
- the product obtained in this manner is the subject-matter of the invention.
- Example 3 Process for production of a medicinal shampoo including stable foam containing carbon dioxide on a skin surface to be treated
- the ingredients from the 3, 4 container compartments of the two-compartment 1 container introduced in Example 1. are helped onto the hairy skin (scalp) surface to get out in a suitable amount in thickness of layer of 2-3 centimetres by the help of the 5 dosing equipment by pressing the 9 press-button of the 5 dosing equipment, where the ingredients stepping into reaction form carbon dioxide gas, this causes vasodilatation during 5-10 minutes in the venous network under the skin. After leaving of the carbon dioxide it is not necessary to wash down the shampoo immediately from the hairy scalp but it is possible to leave on it until it is reasonable according to the therapeutic and/or cosmetic effect.
- Example 4 Process for the production of a massaging (“warming") cream including stable foam containing carbon dioxide on a skin surface to be treated
- the ingredients from the 3, 4 container compartments of the two-compartment 1 container (tube) introduced in Example 2 are helped onto the skin surface covering a group of muscles to be massaged to get out in a suitable amount in thickness of layer of 1,5 - 2 centimetres by manual pressure of the 10 side wall; these ingredients stepping into reaction form carbon dioxide which causes vasodilatation during 5-10 minutes in the venous network under the skin. After leaving of the carbon dioxide it is not necessary to wash down the cream immediately from the covered skin surface but it is possible to leave on it until it is reasonable according to the therapeutic and/or cosmetic effect.
- the group of muscles prepared by the dilatation of the blood vessels can be effectively massaged.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
La présente invention concerne un récipient à deux compartiments remplis fournissant une mousse de dioxyde de carbone. L'invention se caractérise en ce que l'un des compartiments (3) contient un acide et l'autre compartiment (4) contient un carbonate ou un carbonate d'hydrogène. En outre, le récipient contient également (dans au moins l'un des compartiments (3)) un matériau tensioactif (détergeant), des matériaux de bases cosmétiques, de l'eau et éventuellement des produits pharmaceutiques. La libération des ingrédients sur une surface donnée, de préférence la peau, est facilitée par le biais de l'équipement de dosage (5). L'invention concerne également un procédé de préparation d'une composition de mousse contenant du gaz carbonique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP-06-00765 | 2006-10-06 | ||
HU0600765A HUP0600765A2 (en) | 2006-10-06 | 2006-10-06 | Container for stable carbondioxide foam, process for producing stable carbondioxide foam and method for using of foam |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008041045A1 true WO2008041045A1 (fr) | 2008-04-10 |
Family
ID=89987073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2006/000113 WO2008041045A1 (fr) | 2006-10-06 | 2006-12-15 | Récipient à chambres multiples pour la production et la distribution de mousse de dioxyde de carbone, procédé de production et utilisation de ladite mousse |
Country Status (2)
Country | Link |
---|---|
HU (1) | HUP0600765A2 (fr) |
WO (1) | WO2008041045A1 (fr) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008029357A1 (de) * | 2008-06-20 | 2009-12-24 | Schwan-Stabilo Cosmetics Gmbh & Co. Kg | Schäumende kosmetische Zubereitung |
CN102764478A (zh) * | 2011-05-04 | 2012-11-07 | 抛罗根有限公司 | 使用泡腾片剂用于美容护理的装置和方法 |
US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8362091B2 (en) | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8486375B2 (en) | 2003-04-28 | 2013-07-16 | Foamix Ltd. | Foamable compositions |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US8518378B2 (en) | 2003-08-04 | 2013-08-27 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2013096425A3 (fr) * | 2011-12-19 | 2014-03-27 | Colgate-Palmolive Company | Système d'activation de liquide |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8978936B2 (en) | 2010-07-12 | 2015-03-17 | Foamix Pharmaceuticals Ltd. | Apparatus and method for releasing a unit dose of content from a container |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
EP2886625A4 (fr) * | 2012-08-16 | 2016-01-20 | Toyo Aerosol Ind Co | Produit aérosol de formation de mousse |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9516877B2 (en) | 2012-03-30 | 2016-12-13 | Gojo Industries, Inc. | Antimicrobial alcohol foam compositions and methods of preparation |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
WO2019025115A1 (fr) * | 2017-08-02 | 2019-02-07 | Beiersdorf Ag | Produit cosmétique pour le nettoyage du visage |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223245A (en) * | 1990-09-11 | 1993-06-29 | Beecham Inc. | Color change mouthrinse |
FR2738148A1 (fr) * | 1995-08-28 | 1997-03-07 | Codif International Sa | Procede d'application cutanee d'une composition cosmetique aqueuse et procede de conditionnement de ladite composition, prevue pour etre appliquee conformement audit procede d'application cutanee |
US5804546A (en) * | 1995-05-27 | 1998-09-08 | Cussons (International) Limited | Cleaning composition |
WO2001036018A2 (fr) * | 1999-11-08 | 2001-05-25 | Capnia Incorporated | Methode et appareil de co-application de gaz et de medicaments pour potentialiser leur action soulageant les maux de tete, l'angine et d'autres maux |
EP1133983A2 (fr) * | 1998-11-10 | 2001-09-19 | Color Access, Inc. | Produits démaquillants auto-moussants |
US6583103B1 (en) * | 2002-08-09 | 2003-06-24 | S.C. Johnson & Son, Inc. | Two part cleaning formula resulting in an effervescent liquid |
GB2386604A (en) * | 2002-03-18 | 2003-09-24 | Pz Cussons | Personal cleansing composition |
-
2006
- 2006-10-06 HU HU0600765A patent/HUP0600765A2/hu unknown
- 2006-12-15 WO PCT/HU2006/000113 patent/WO2008041045A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223245A (en) * | 1990-09-11 | 1993-06-29 | Beecham Inc. | Color change mouthrinse |
US5804546A (en) * | 1995-05-27 | 1998-09-08 | Cussons (International) Limited | Cleaning composition |
FR2738148A1 (fr) * | 1995-08-28 | 1997-03-07 | Codif International Sa | Procede d'application cutanee d'une composition cosmetique aqueuse et procede de conditionnement de ladite composition, prevue pour etre appliquee conformement audit procede d'application cutanee |
EP1133983A2 (fr) * | 1998-11-10 | 2001-09-19 | Color Access, Inc. | Produits démaquillants auto-moussants |
WO2001036018A2 (fr) * | 1999-11-08 | 2001-05-25 | Capnia Incorporated | Methode et appareil de co-application de gaz et de medicaments pour potentialiser leur action soulageant les maux de tete, l'angine et d'autres maux |
GB2386604A (en) * | 2002-03-18 | 2003-09-24 | Pz Cussons | Personal cleansing composition |
US6583103B1 (en) * | 2002-08-09 | 2003-06-24 | S.C. Johnson & Son, Inc. | Two part cleaning formula resulting in an effervescent liquid |
Cited By (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
US8741265B2 (en) | 2002-10-25 | 2014-06-03 | Foamix Ltd. | Penetrating pharmaceutical foam |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8486375B2 (en) | 2003-04-28 | 2013-07-16 | Foamix Ltd. | Foamable compositions |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8362091B2 (en) | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8518378B2 (en) | 2003-08-04 | 2013-08-27 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8703105B2 (en) | 2003-08-04 | 2014-04-22 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US9549898B2 (en) | 2007-12-07 | 2017-01-24 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
DE102008029357A1 (de) * | 2008-06-20 | 2009-12-24 | Schwan-Stabilo Cosmetics Gmbh & Co. Kg | Schäumende kosmetische Zubereitung |
US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9572775B2 (en) | 2009-07-29 | 2017-02-21 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US10946101B2 (en) | 2009-10-02 | 2021-03-16 | Vyne Therapeutics Inc. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8992896B2 (en) | 2009-10-02 | 2015-03-31 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
US8978936B2 (en) | 2010-07-12 | 2015-03-17 | Foamix Pharmaceuticals Ltd. | Apparatus and method for releasing a unit dose of content from a container |
US9463919B2 (en) | 2010-07-12 | 2016-10-11 | Foamix Pharmaceuticals Ltd. | Apparatus and method for releasing a unit dose of content from a container |
CN102764478A (zh) * | 2011-05-04 | 2012-11-07 | 抛罗根有限公司 | 使用泡腾片剂用于美容护理的装置和方法 |
EP2609830A1 (fr) * | 2011-05-04 | 2013-07-03 | Pollogen Ltd | Appareil et procédé permettant d'utiliser des comprimés effervescents de soin cosmétique |
WO2013096425A3 (fr) * | 2011-12-19 | 2014-03-27 | Colgate-Palmolive Company | Système d'activation de liquide |
CN104394937A (zh) * | 2011-12-19 | 2015-03-04 | 高露洁-棕榄公司 | 液体活化系统 |
CN104394937B (zh) * | 2011-12-19 | 2017-09-22 | 高露洁-棕榄公司 | 液体活化系统 |
AU2012359083B2 (en) * | 2011-12-19 | 2015-11-26 | Colgate-Palmolive Company | Liquid activation system |
US10238590B2 (en) | 2011-12-19 | 2019-03-26 | Colgate-Palmolive Company | Liquid activation system |
US9943080B2 (en) | 2012-03-30 | 2018-04-17 | Gojo Industries, Inc. | Antimicrobial alcohol foam compositions and methods of preparation |
US9516877B2 (en) | 2012-03-30 | 2016-12-13 | Gojo Industries, Inc. | Antimicrobial alcohol foam compositions and methods of preparation |
EP2886625A4 (fr) * | 2012-08-16 | 2016-01-20 | Toyo Aerosol Ind Co | Produit aérosol de formation de mousse |
US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
WO2019025115A1 (fr) * | 2017-08-02 | 2019-02-07 | Beiersdorf Ag | Produit cosmétique pour le nettoyage du visage |
CN110997076A (zh) * | 2017-08-02 | 2020-04-10 | 拜尔斯道夫股份有限公司 | 用于面部清洁的化妆品 |
Also Published As
Publication number | Publication date |
---|---|
HUP0600765A2 (en) | 2008-10-28 |
HU0600765D0 (en) | 2006-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008041045A1 (fr) | Récipient à chambres multiples pour la production et la distribution de mousse de dioxyde de carbone, procédé de production et utilisation de ladite mousse | |
US8697621B2 (en) | Surfactant product comprising two distinct effervescent compositions | |
JP3186879U (ja) | 炭酸パック | |
JPS609009B2 (ja) | 発泡性浴用剤 | |
US8697037B2 (en) | Composition | |
JP2013129654A (ja) | クエン酸・重曹を含む錠剤及びその製造方法、並びに、高濃度の重炭酸イオンを含んだ美容用材及び該美容用材を使用した美容方法 | |
KR20180080412A (ko) | 천연허브파우더를 함유하는 태블릿 염모제 조성물 | |
EP1319396B1 (fr) | Compositions de bains cosmétiques basées sur les herbes et les herbes substances moussantes, et matériau d'emballage contenant cette composition | |
KR20190101247A (ko) | 녹차를 이용한 입욕제 및 방향제 제조방법 | |
JP2009051770A (ja) | 食欲抑制用組成物 | |
JP2006131546A (ja) | 白樺樹液含有入浴剤 | |
KR102149469B1 (ko) | 수소를 이용한 뜸장치 | |
KR100206721B1 (ko) | 화장용 방취 및 항균 조성물 | |
JPS6216409A (ja) | 塩化ナトリウム入り美容剤 | |
CN101731893A (zh) | 颈椎保健枕芯 | |
JPH04264186A (ja) | エヤゾール組成物 | |
KR20140115074A (ko) | 탄산수가 포접된 폴리머 매트릭스를 유효성분으로 함유하는 클렌저 화장료 조성물 | |
RU2813623C1 (ru) | Жидкий бальнеологический концентрат и ампула с мерной шкалой и устройством для удобного дозирования бальнеологического концентрата | |
JPH01294616A (ja) | シャワー用芳香剤 | |
RU2215519C2 (ru) | Косметическая маска и способ ее использования | |
KR20070040980A (ko) | 발포성 세안 및 목욕 제제 | |
JPH0977675A (ja) | 生薬配合発泡錠 | |
JP2010024184A (ja) | むくみ改善組成物およびそれを利用したむくみ改善方法 | |
RU1814554C (ru) | Дезодорирующее средство | |
KR20010078904A (ko) | 미용효과가 우수한 피부세정제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06831513 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06831513 Country of ref document: EP Kind code of ref document: A1 |